flip, thanks again for the deep research. I also use the 80% responders data point as a key indicator that with either trial design, DCVax-L will gain approval.
Flipper, I don't get what you mean by this alternative. Are you saying that you don't know what they're doing with the pseudo-progression patients in the trial?
You've now got 5 arms as your current possibility. Is this a guess? I don't have any knowledge of the trial other than the basics, so I'll rely on your interpretation. But I've never heard of any FDA trials with so many arms, based on so many variables. All the trial designs I've seen have been very straight forward.
News 
Market Data 
Discover 
